Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

Akari Therapeutics PLC (AKTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Akari Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.5200 -0.0100    -0.65%
17/05 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 20,155
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 1.4700 - 1.6036
Akari Therapeutics 1.5200 -0.0100 -0.65%

Akari Therapeutics PLC Company Profile

 
Get an in-depth profile of Akari Therapeutics PLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

11

Equity Type

ADR

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Contact Information

Address 22 Boston Wharf Road Floor 7
Boston, 02210
United States
Phone 929 274 7510
Fax 929 274 7553

Top Executives

Name Age Since Title
Raymond Prudo-Chlebosz 80 2015 Chairman
Michael J. Grissinger 71 2018 Independent Director
Donald A. Williams 66 2016 Independent Director
Mohamed Wa'el Ahmed Hashad 62 2023 Independent Director
Samir Rashmikant Patel 55 2023 Interim CEO & Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AKTX Comments

Write your thoughts about Akari Therapeutics PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Piter Max
Piter Max Jan 28, 2021 7:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong Sell
Nick Landis
Nick Landis Sep 29, 2020 6:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Akari Therapeutics plc as a new IPPF Corporate Council member!
Joseph Mission
KingxFisher Oct 11, 2019 1:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Holddddd!
Sean Gacevic
Sean Gacevic Oct 11, 2019 1:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I agree long term will be rewarding! Load up while you still can
KEN LNSS
KEN LNSS Oct 02, 2019 2:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sell
Piter Max
Piter Max Mar 15, 2019 10:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hold or Sell???
Eddie Amar
Eddie Amar Mar 15, 2019 10:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sell.,. I sold in the morning, . lost some money
Piter Max
Piter Max Mar 14, 2019 12:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy or sell??
Piter Max
Piter Max Mar 14, 2019 10:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA
Piter Max
Piter Max Mar 14, 2019 9:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics's Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
jacob capeles
jacob capeles Mar 14, 2019 9:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why u say that
Piter Max
Piter Max Mar 14, 2019 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
crazy people!!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email